Identifying Key The...
Health Care: Drugs
Dr. Reddy Laboratories Ltd. (RDY: NYSE)
$32.73 -0.03 | -0.09%
02/09/12 - 04:03 PM ET
251.35K / 238.70K
Vol / Avg. Vol:33.07 / 32.76
Open / Prev. Close:32.70 - 33.07
Today's Range:28.75 - 39.37
52 Wk Range:11.32%
Performance YTD:TheStreet Rating:
Portfolios with RDY
- Portfolio NameUser Type
- Contributor6 Best-Performing Emerging ...
- Contributor7 India Stocks With Upside
- ContributorPharma Short Squeezes for 2011
- UserFranks
- Contributor6 Indian Growth Stocks With...
- Contributor5 Drug Stocks With Upside P...
- ContributorTop 10 Emerging Markets Sto...
- UserMy Portfolio
- ContributorTop 10 Emerging Markets Sto...
- ProFidelity Select Pharmaceuti...
Latest RDY Headlines from TheStreet
- Dr. Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript 02.03.12 | 05:02 pm
- Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript 10.25.11 | 03:10 pm
- 6 Best-Performing Emerging Market ADRs 10.13.11 | 05:10 pm
- 8 New ETF Gems to Trade 08.22.11 | 06:08 am
- 5 Winners in Emerging Markets ADRs 07.29.11 | 12:07 pm
- Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript 07.20.11 | 10:07 pm
- Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY) 06.13.11 | 09:06 am
- 7 India Stocks With Upside 05.27.11 | 12:05 pm
- Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY) 04.25.11 | 06:04 pm
- 5 Pharma Stocks That Could Get Squeezed Higher 04.14.11 | 12:04 pm
Press Releases for RDY
- Dr. Reddy’s Q3 FY12 Financial Results - Business Wire 02.03.12 | 05:02 am
- Dr. Reddy's To Release Q3 FY12 Results On February 3, 2012 - Business Wire 01.16.12 | 05:01 am
- Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States - Business Wire 10.25.11 | 09:10 am
- Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States - Business Wire 10.25.11 | 08:10 am
- Dr. Reddy’s Q2 FY12 Financial Results - Business Wire 10.25.11 | 06:10 am
- Dr. Reddy’s Announces The Launch Of Rivastigmine Tartrate Capsules - Business Wire 09.22.11 | 09:09 am
- Dr. Reddy’s Announces Start Of Phase II Study With The CETP Inhibitor, DRL-17822 In Dyslipidemia Patients - Business Wire 09.02.11 | 03:09 am
- Dr. Reddy’s Announces Settlement Of Lipitor® (atorvastatin) ANDA Litigation With Pfizer - Business Wire 08.31.11 | 11:08 am
- Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl And Pseudoephedrine HCl Extended Release Tablets - Business Wire 08.30.11 | 01:08 pm
- FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan - Business Wire 07.28.11 | 03:07 am
Partner Headlines for RDY
- Credit Suisse Downgrades Dr Reddys Laboratories from Outperform to Neutral - Benzinga 02.07.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca - Press Releases - Zacks 02.07.12 | 09:02 am
- Dr. Reddy's Going Strong - Analyst Blog - Zacks 02.06.12 | 10:02 am
- Zacks #5 Rank Additions for Monday - Tale of the Tape - Zacks 01.23.12 | 09:01 am
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 01.19.12 | 09:01 am
- The Zacks Analyst Blog Highlights: Teva Pharmaceuticals, Mylan, Watson Pharma, Dr. Reddy's and Novartis - Press Releases - Zacks 12.30.11 | 09:12 am
- Ring in Generics in 2012 and Beyond - Analyst Blog - Zacks 12.29.11 | 08:12 am
- Earnings Beat for Teva; View Adjusted - Analyst Blog - Zacks 11.03.11 | 09:11 am
- Dr. Reddy's Continues to Grow - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 10 Dividend Stocks With Bearish Trends Despite Explosive Earnings Growth - Seeking Alpha 09.25.11 | 09:09 am
